At 5:20 PM this Wednesday, the pharmaceutical companies Moderna and Merck saw their stock prices soar by 119% and 11.10%, respectively. The increase in share prices occurred after the two giants announced, in a joint press release, the achievement of "positive results" in the clinical trial of an experimental and pioneering therapy for melanoma, the most common skin cancer. Specifically, it is a vaccine (autogene intismere) that, in combination with an immunotherapy called Keytruda (pembrolizumab), is being evaluated as an adjuvant treatment to reduce the risk of melanoma recurring or spreading after tumor removal.